T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine

Anti-SARS-CoV-2 antibodies are crucial for protection from future COVID-19 infections, limiting disease severity, and control of viral transmission. While patients with the most common type of hematologic malignancy, B cell lymphoma, often develop insufficient antibody responses to messenger RNA (mR...

Descripción completa

Detalles Bibliográficos
Autores principales: Atanackovic, Djordje, Kreitman, Robert J, Cohen, Jeffrey, Hardy, Nancy M, Omili, Destiny, Iraguha, Thierry, Burbelo, Peter D, Gebru, Etse, Fan, Xiaoxuan, Baddley, John, Luetkens, Tim, Dahiya, Saurabh, Rapoport, Aaron P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295666/
https://www.ncbi.nlm.nih.gov/pubmed/35851312
http://dx.doi.org/10.1136/jitc-2022-004953

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295666/
https://www.ncbi.nlm.nih.gov/pubmed/35851312
http://dx.doi.org/10.1136/jitc-2022-004953

Ejemplares similares